ecteinascidin 743 has been researched along with Leiomyosarcoma, Epithelioid in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (8.70) | 29.6817 |
| 2010's | 27 (58.70) | 24.3611 |
| 2020's | 15 (32.61) | 2.80 |
| Authors | Studies |
|---|---|
| Grimison, P; King, D; Thomson, K; Zhou, DD | 1 |
| Aicher, L; Black, G; Cranmer, LD; He, Q; Hermida de Viveiros, P; Johnson, R; Jones, RL; Loggers, ET; Maxwell, S; McDonnell, S; Moore, R; Pollack, SM; Smythe, KS; Wagner, MJ; Zhang, Y | 1 |
| Szkandera, J | 1 |
| Bakhshi, S; Pushpam, D; Sasi, A | 1 |
| Chib, S; Gogia, A | 1 |
| Özdemir, N; Özet, A; Sütcüoğlu, O; Yazıcı, O | 1 |
| Archambaud, B; Pautier, P; Tanguy, ML | 1 |
| Casali, PG; Celant, S; Comandone, A; Di Segni, S; Napolitano, A; Olimpieri, PP; Russo, P; Sanfilippo, R; Vincenzi, B | 1 |
| Aubry, S; Chaigneau, L; Charon Barra, C; Hervieu, A; Isambert, N; Jary, M; Kalbacher, E; Meynard, G; Nerich, V; Neumann, F | 1 |
| Aquilano, M; Becherini, C; Campanacci, DA; Francolini, G; Greto, D; Livi, L; Loi, M; Mangoni, M; Melica, ME; Salvatore, G; Salvestrini, V; Santini, C; Sottili, M; Talamonti, C; Valzano, M | 1 |
| Ae, K; Fukuda, N; Hayakawa, K; Hayashi, N; Matsumoto, S; Minami, Y; Nakano, K; Ohmoto, A; Oki, R; Ono, M; Saito, M; Sato, Y; Suto, H; Takahashi, S; Tanizawa, T; Tomomatsu, J; Udagawa, S; Urasaki, T; Wang, X; Yunokawa, M | 1 |
| Meeus, P; Ray-Coquard, I; Turinetto, M | 1 |
| Blay, JY; de Sande González, LM; Kasper, B; Le Cesne, A; Martin-Broto, J | 1 |
| Schuetze, S | 1 |
| Reichardt, P | 1 |
| Demetri, GD; Elias, A; Hamm, J; Hensley, ML; Jones, RL; Knoblauch, R; Maki, RG; McCarthy, S; Milhem, M; Parekh, T; Patel, S; Schuetze, SM; Van Tine, BA; von Mehren, M; Wang, G | 1 |
| Garcia Del Muro, X; Ibrahim, T; Jones, RL; Le Cesne, A; Menge, F | 1 |
| Merimsky, O; Shamai, S | 1 |
| Kato, S; Nozaki, Y; Takagi, T; Yamaguchi, S | 1 |
| Charlson, J; Chawla, SP; D'Amato, G; Demetri, GD; Forscher, C; Hensley, ML; Kaiser, P; Knoblauch, R; Livingston, M; Maki, RG; McCarthy, S; Parekh, T; Patel, S; Reed, DR; Rushing, D; Ryan, CW; Seth, R; Singh, A; von Mehren, M; Wang, G | 1 |
| Casali, PG; Sanfilippo, R | 1 |
| Ahrens, M; Bauer, S; Grabellus, F; Hoiczyk, M; Podleska, L; Pöttgen, C; Schuler, M; Schwindenhammer, B; Taeger, G | 1 |
| Blay, JY; Casali, P; Le Cesne, A; Nieto, A; Tanović, A | 1 |
| Aglietta, M; Aliberti, S; Galizia, D; Grignani, G; Nuzzo, AM; Palesandro, E; Pignochino, Y | 1 |
| Elowsson, C; Krarup-Hansen, A; Mouritsen, LS; Safwat, A; Schack, LH | 1 |
| Hohenberger, P; Kasper, B; Mathew, M; Pink, D; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Alexandre, J; Bertucci, F; Bompas, E; Chevreau, C; Collard, O; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Guillemet, C; Isambert, N; Lacas, B; Lavau-Denes, S; Le Cesne, A; Pautier, P; Penel, N; Piperno-Neumann, S; Selle, F; Soulié, P; Thyss, A; Toulmonde, M | 1 |
| Grignani, G; Martín-Broto, J; Reichardt, P; Schuler, M | 1 |
| Dean, A; Demetri, GD; Elias, A; Ganjoo, K; Hensley, ML; Jones, RL; Khokhar, NZ; Knoblauch, RE; Maki, RG; Milhem, M; Parekh, TV; Park, YC; Patel, SR; Schuetze, SM; Spira, A; Staddon, A; Tawbi, H; Van Tine, BA; von Mehren, M | 1 |
| Balzarini, L; Bastoni, S; Bertuzzi, AF; Daolio, P; De Sanctis, R; Lutman, FR; Marchetti, S; Marrari, A; Mussi, C; Quagliuolo, V; Santoro, A | 1 |
| Basso, U; Brunello, A; Diminutto, A; Maruzzo, M; Rastrelli, M | 1 |
| Amadori, D; Bongiovanni, A; Cavaliere, D; De Vita, A; Ibrahim, T; La Manna, F; Liverani, C; Mercatali, L; Oboldi, D; Pieri, F; Ricci, M; Riva, N; Verdecchia, GM | 1 |
| Gronchi, A; Saponara, M; Stacchiotti, S | 1 |
| von Mehren, M; Zijoo, R | 1 |
| Amunni, G; Lavacchi, D; Mazzei, T; Montelatici, S; Tavella, K; Vannini, L; Villanucci, A | 1 |
| Fader, AN; Ricci, S; Stone, RL | 1 |
| Blay, JY; Buckley, B; Elsayed, YA; Fanucchi, MP; Gilles, L; Le Cesne, A; Lebedinsky, C; Ray-Coquard, I; Samuels, BL; von Mehren, M | 1 |
| Adenis, A; Hollebecque, A; Lebedinsky, C; Penel, N; Taieb, S | 1 |
| Baker, LH; Blay, JY; Chawla, SP; Demetri, GD; Elsayed, YA; Gómez, J; Hande, KR; Izquierdo, MA; Keohan, ML; Le Cesne, A; Lebedinsky, C; Park, YC; Ritch, P; Samuels, BL; Schuetze, S; von Mehren, M | 1 |
| Demetri, GD; George, S; Hartzell, TL; Morgan, J; Orgill, DP; Polson, K; Sinha, I; Theman, TA | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Corrado, G; Ferrandina, G; Fuoco, G; Lucidi, A; Salutari, V | 1 |
| Ray-Coquard, I | 1 |
| Banerjee, S; Casali, PG; D'Incalci, M; Dei Tos, AP; Grosso, F; Jones, RL; Judson, I; Pilotti, S; Raspagliesi, F; Sanfilippo, R | 1 |
| Blessing, JA; Burke, JJ; Hensley, ML; Monk, BJ; Muller, CY; Street, DG | 1 |
| Cowan, C; Koontz, MZ; Monk, BJ; Saffari, B; Tewari, D; Wallick, AC | 1 |
10 review(s) available for ecteinascidin 743 and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Leiomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2023 |
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Humans; Leiomyosarcoma; Liposarcoma; Quality of Life; Randomized Controlled Trials as Topic; Sarcoma; Trabectedin | 2020 |
Preserving quality of life as a key treatment goal in advanced soft tissue sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Male; Patient Reported Outcome Measures; Quality of Life; Sarcoma; Trabectedin; Young Adult | 2018 |
Prolonged disease stability with trabectedin in a heavily pretreated elderly patient with metastatic leiomyosarcoma of the thigh and renal failure: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease Progression; Humans; Leiomyosarcoma; Lung Neoplasms; Male; Renal Insufficiency; Salvage Therapy; Tetrahydroisoquinolines; Time Factors; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome | 2013 |
The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Dioxoles; Drug Design; Humans; Leiomyosarcoma; Liposarcoma; Prognosis; Tetrahydroisoquinolines; Time Factors; Trabectedin | 2016 |
Efficacy of trabectedin for the treatment of liposarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Chemotherapy, Adjuvant; Deoxycytidine; Diagnostic Errors; Dioxoles; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Hysterectomy; Indazoles; Laparoscopy; Leiomyoma; Leiomyosarcoma; Morcellation; Neoplasm Staging; Pyrimidines; Sulfonamides; Taxoids; Tetrahydroisoquinolines; Trabectedin; Uterine Myomectomy; Uterine Neoplasms | 2017 |
Recognition of a new chemotherapeutic vesicant: trabectedin (ecteinascidin-743) extravasation with skin and soft tissue damage.
Topics: Aged, 80 and over; Antineoplastic Agents, Alkylating; Catheterization, Central Venous; Device Removal; Dioxoles; Drainage; Extravasation of Diagnostic and Therapeutic Materials; Female; Follow-Up Studies; Humans; Immunohistochemistry; Infusions, Intravenous; Irritants; Leiomyosarcoma; Necrosis; Severity of Illness Index; Skin Ulcer; Soft Tissue Injuries; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2009 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
An increasing role for trabectedin in gynecological cancers: efficacy in uterine sarcomas.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Female; Humans; Leiomyosarcoma; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2011 |
10 trial(s) available for ecteinascidin 743 and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; B7-H1 Antigen; Humans; Leiomyosarcoma; Leukocytes, Mononuclear; Liposarcoma; Trabectedin | 2022 |
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Progression-Free Survival; Time Factors; Trabectedin; Young Adult | 2018 |
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Survival Analysis; Trabectedin | 2019 |
Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Drug Administration Schedule; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Drug Therapy, Combination; Female; Gemcitabine; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2015 |
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Female; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2015 |
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2016 |
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Liposarcoma; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2008 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Australia; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Humans; Ifosfamide; Infusions, Intravenous; Kaplan-Meier Estimate; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Staging; North America; Proportional Hazards Models; Risk Assessment; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Failure; Young Adult | 2009 |
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2012 |
26 other study(ies) available for ecteinascidin 743 and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results.
Topics: Antineoplastic Agents, Alkylating; Australia; Clinical Trials as Topic; Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2022 |
Keeping up the 'race pace' in a patient with nonuterine leiomyosarcoma.
Topics: Clinical Trials, Phase III as Topic; Doxorubicin; Humans; Leiomyosarcoma; Male; Randomized Controlled Trials as Topic; Trabectedin | 2022 |
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.
Topics: Doxorubicin; Humans; Leiomyosarcoma; Trabectedin | 2022 |
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.
Topics: Doxorubicin; Humans; Leiomyosarcoma; Trabectedin | 2022 |
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma.
Topics: Doxorubicin; Humans; Leiomyosarcoma; Trabectedin | 2022 |
Doxorubicin plus trabectedin for metastatic or unresectable leiomyosarcoma - Authors' reply.
Topics: Doxorubicin; Humans; Leiomyosarcoma; Trabectedin | 2022 |
Trabectedin use in soft-tissue sarcoma patients in a real-world setting: Data from an Italian national drug-access registry.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Male; Registries; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2023 |
Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2022 |
Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells.
Topics: Antineoplastic Agents, Alkylating; Fibrosarcoma; Humans; Leiomyosarcoma; Liposarcoma; Radiation-Sensitizing Agents; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Tumor Microenvironment | 2022 |
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study.
Topics: Adult; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2023 |
Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so in other soft tissue sarcomas.
Topics: Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Trabectedin | 2021 |
Uncertainties that threaten the benefit/risk balance in early treatment lines for advanced or metastatic soft tissue sarcoma.
Topics: Aged, 80 and over; Chemoradiotherapy; Disease Progression; Fatal Outcome; Humans; Leiomyosarcoma; Lumbar Vertebrae; Lung; Lung Neoplasms; Male; Positron Emission Tomography Computed Tomography; Risk Assessment; Spinal Neoplasms; Trabectedin | 2021 |
Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Retrospective Studies; Sarcoma; Survival Rate; Trabectedin; Young Adult | 2018 |
[An Effective Treatment of Relapsed Leiomyosarcoma with Fourth-Line Trabectedin].
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2019 |
The intriguing patterns of tumor response to trabectedin.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Liposarcoma, Myxoid; Molecular Targeted Therapy; Sarcoma; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Outcome; Tumor Microenvironment; Uterine Neoplasms | 2013 |
Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dioxoles; Disease Progression; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2013 |
The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chondrosarcoma; Denmark; Dioxoles; Female; Humans; Hyponatremia; Karnofsky Performance Status; Leiomyosarcoma; Liposarcoma; Middle Aged; Multivariate Analysis; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2015 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Long-term response to first-line trabectedin in an elderly female patient with a metastatic leiomyosarcoma unfit for anthracycline.
Topics: Aged; Antineoplastic Agents; Dioxoles; Fatal Outcome; Female; Humans; Leiomyosarcoma; Rectal Neoplasms; Tetrahydroisoquinolines; Time Factors; Trabectedin | 2016 |
Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
Topics: Aged; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Leiomyosarcoma; Neoplasm Metastasis; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2017 |
Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials, Phase II as Topic; Dioxoles; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Peritoneal Neoplasms; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2010 |
Prolonged clinical response to trabectedin in a heavily pretreated patient with advanced uterine leiomyosarcoma: a case report and literature review.
Topics: Dioxoles; Female; Humans; Leiomyosarcoma; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2011 |
Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dioxoles; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Middle Aged; Retrospective Studies; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2011 |
Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Drug Administration Schedule; Drugs, Investigational; Female; Humans; Leiomyosarcoma; Lung Neoplasms; Neoplasm Recurrence, Local; Tetrahydroisoquinolines; Trabectedin; Uterine Neoplasms | 2006 |